All In Biotech

Drug Trial Radar · NCT00906880

Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase

Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Stage

Last checked: Nov 20, 2026Latest source record: May 31, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

630

Actual

Start

Apr 2009

Primary completion

Sep 2010

Study completion Jan 2013

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Public Health, Democratic Republic of the Congo; Swiss Tropical & Public Health Institute
First posted
May 21, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, open label, uncontrolled phase IIIb study of therapeutic use of the combination of nifurtimox and eflornithine (NECT) for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT) in the meningo-encephalitic phase. Overall objectives: Assess the clinical tolerability, feasibility and effectiveness of NECT co-administration to treat patients with T.b. gambiense human African trypanosomiasis (HAT) in the meningo-encephalitic phase in actual real-life conditions (regular treatment centers of the National HAT Control Programme, NGO treatment centers). Primary objective: * Assess the clinical response of the NECT co-administration under field conditions. Secondary objectives: * Assess the incidence and type of adverse events (AE), and the capacity of the treatment centers to deal with these. * Assess the feasibility of the implementation of the NECT coadministration by the health center. * Assess the effectiveness of the NECT co-administration at 24\* months after treatment.

Conditions

  • Human African Trypanosomiasis

Interventions

  • Nifurtimox-Eflronithine Combination Treatment (NECT)Drug

    co-administration of nifurtimox (10 days, 15 mg/kg/day, p.o. TID) and eflornithine (7 days, 400 mg/kg/day, i.v. BID)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients discharged alive from the hospital or the treatment center

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • HGR (General Reference Hospital) Bandundu

    Bandundu, Bandundu, Republic of the Congo

  • HGR (General Reference Hospital) Kwamouth

    Kwamouth, Bandundu, Republic of the Congo

  • HGR (General Reference Hospital) Yasa Bonga

    Yasa Bonga, Bandundu, Republic of the Congo

  • CDTC (Centre de Dépistage, Traitement et Contrôle) Katanda

    Katanda, East Kasai, Republic of the Congo

  • CRT (Centre de Réference et de Traitement) Dipumba, Dipumba general hospital

    Mbuji Mayi, East Kasai, Republic of the Congo

  • HGR (General Reference Hospital) Ngandajika

    Ngandajika, East Kasai, Republic of the Congo

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.